GLP-1 Studio
GLP-1 Studio Daily
How did GLP-1s compare with metformin?
0:00
-3:31

How did GLP-1s compare with metformin?

Plus eating habits, Wegovy for MASH and Allergan face studies
A white blood glucose meter reading 103 mg/dL on a tan background
Photo by i-SENS, USA on Pexels

Good morning! GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes. Also today: how eating habits changed for 38 people starting semaglutide or tirzepatide, Wegovy liver results in 106 people with MASH without obesity, and two Allergan face studies in people on GLP-1s. Listen to me read them above, or read the key details below.

Daily Roundup:

  1. GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes (HCPLive)

  2. A small study tracks how eating habits change in the first three months on semaglutide or tirzepatide (News-Medical)

  3. Wegovy improved liver markers in people with MASH who do not have obesity (HCPLive)

  4. Allergan reports two studies of face and skin treatments in people taking GLP-1 medications (Allergan Aesthetics)


GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes

Key Details:

  • A study compared GLP-1 drugs with metformin in more than 256,000 adults with prediabetes and obesity, using health records from 104 institutions over about three years.

  • Blood sugar went back to normal in 37.3 percent of people on GLP-1 drugs and 29.3 percent of people on metformin.

  • Type 2 diabetes developed in 25.1 percent of people on GLP-1 drugs and 37 percent of people on metformin, and the GLP-1 group had a lower risk of heart failure, stroke and heart attack.

  • The study looked back at records, so it cannot prove the drugs caused the results, and it has not been peer reviewed, meaning outside scientists have not checked it yet. Dr. Vinicius de Sousa Barzon Serra of the Mayo Clinic said, “Metformin is still a first-line treatment choice.”

Source: HCPLive


A small study tracks how eating habits change in the first three months on semaglutide or tirzepatide

Key Details:

  • Researchers in Italy and the United Kingdom followed 38 adults without diabetes who started semaglutide or tirzepatide.

  • After three months, people reported fewer cravings for sweet and savory foods, feeling fuller after meals, and eating fewer meals a day.

  • 84 percent reported much smaller portions, and people lost an average of 7.2 kilograms, about 16 pounds.

  • The authors said smaller portions can mean less protein, fiber, fluid, vitamins and minerals, and called for nutrition monitoring. It was a small pilot study with no comparison group.

Source: News-Medical


Wegovy improved liver markers in people with MASH who do not have obesity

Key Details:

  • MASH is a serious liver disease with fat and inflammation in the liver that can lead to scarring. A new look at Novo Nordisk’s ESSENCE trial studied 106 people with MASH and liver scarring whose BMI was below 27.

  • After 72 weeks, people on Wegovy had better liver enzyme levels and better blood markers of scarring than people on placebo.

  • Dr. Jörn Schattenberg, who presented the analysis, said, “we looked at the BMI below 27 and compared it to the other BMI categories, and the efficacy is actually the same.”

  • Novo Nordisk said this kind of after-the-fact analysis raises ideas that need more study.

Source: HCPLive and Novo Nordisk


Allergan reports two studies of face and skin treatments in people taking GLP-1 medications

Key Details:

  • Allergan presented both studies at the American Society for Dermatologic Surgery meeting in San Diego. Both looked at its hyaluronic acid fillers in adults on steady doses of GLP-1 medications.

  • In one study, 30 people on GLP-1 medications got fillers, Botox and a skincare routine, and they reported higher satisfaction with how their face and skin looked.

  • Early results from the other study, covering 25 of its 75 people, found 95.7 percent were satisfied or very satisfied that they still looked like themselves.

  • Both studies tested Allergan’s own products, with no comparison group, and people rated the results themselves.

Source: Allergan Aesthetics


Learn More

Amanda Bonello

This is a reader-supported publication, thank you so much for your support. 💖

Instagram · TikTok · LinkedIn


Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured.

Discussion about this episode

User's avatar

Ready for more?